| Biomarker ID | 634 |
| PMID | 21504557 |
| Year | 2011 |
| Biomarker | NY-ESO-1 + XAGE-1b + SSX-2,4 + AMACR + p90 + LEDGF + PSA Index |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (AMACR): Primary bile acid biosynthesis, Bile acids and bile salt biosynthesis, Peroxisomal lipid metabolism, Bile acid and bile salt biosynthesis via 7-alpha-hydroxycholesterol, Bile acid and bile salt metabolism Pathways Include (TFRC):- Iron metabolism in placenta,FYVE-finger proteins in vesicle transport, HNF3B pathway, Thymic stromal lymphopoietin (TSLP) pathway, HIF-1 transcriptional activity in hypoxia Pathways Include(PSIP1):-Integration of provirus,HIV life cycle early phase, APOBEC3G-mediated resistance to HIV-1 infection,Interactions of HIV Vpr protein with host cellular proteins, HIV life cycle Pathways include(KLK3):-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Prostate Cancer Vs BPH |
| Type of Biomarker | Diagnostic |
| Cohort | A total of 124 healthy donors along with 121 patients with BPH (or Prostatis) and 131 patients with prostate cancer were chosen for the study. |
| Senstivity | 79% (103/131) |
| Specificity | 84% (102/121) |
| AUC | 0.91 |
| Accuracy | 81% |
| Level Of Significance | LEDGF, p90, SSX-2, 4, XAGE-1b: p<0.001; NY-ESO-1: p=0.029; AMACR: NS |
| Method Used | SeroMAP-based assays and ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CTAG1B, XAGE1B, SSX2, SSX4, AMACR, TFRC, PSIP1, KLK3 |